DUBLIN--(BUSINESS WIRE)--The "2018 Short Bowel Syndrome Drug Development - Pipeline Analysis Report" report has been added to ResearchAndMarkets.com's offering.
Over 15 companies and universities are focusing on developing treatment options for Short Bowel Syndrome.
This report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Short Bowel Syndrome pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Short Bowel Syndrome pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
- Hanmi Pharmaceuticals
- Naia Ltd
- Napo Pharmaceuticals
- Nutrinia Ltd
- OxThera AB
- Sancilio & Company Inc
- Shire Plc
- Zealand Pharma AS
Key Topics Covered
1 Table of Contents
2 Short Bowel Syndrome Pipeline Analysis
3 Short Bowel Syndrome - Company-wise Pipeline Analysis
4 Short Bowel Syndrome R&D Pipeline Snapshots
5 Recent Developments in Short Bowel Syndrome Pipeline
For more information about this report visit https://www.researchandmarkets.com/research/75333q/2018_pipeline?w=4